Evidence suggests a greater prevalence of fibromyalgia among people with Behçet's disease than in the general population. Just as fibromyalgia appears to be more prevalent among women than men in the ...

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine ("PIM") designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the ...

Please provide your email address to receive an email when new articles are posted on . The rare and complex Behcet’s disease is often misdiagnosed or undiagnosed, leading to significant, but ...

The Orphan Drug designation was supported by data from an open-label phase 2 trial that included 8 adult patients with mild to moderate Behçet disease and active oral and/or genital ulcers. The Food ...

Please provide your email address to receive an email when new articles are posted on . Patients with vascular manifestations of Behçet’s disease who received treatment with anticoagulants did not ...

The MarketWatch News Department was not involved in the creation of this content. -- Study results support advancing SGX945 in this difficult-to-treat orphan disease -- Results suggest potential ...

LONDON--(BUSINESS WIRE)--According to a recent Technavio report, the Behcet's disease therapeutics market is expected to grow by USD 224.55 million during 2019-2023. Growth in the Behcet's disease ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Behcet's Disease pipeline constitutes 4+ key companies continuously working towards developing 4+ ...

PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (“PIM”) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the ...

PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...